The DOI matches its Crossref record; 32 of the 33 references it cites were found in a registry or an index.
Minocycline at 2 Different Dosages vs Placebo for Patients With Mild Alzheimer Disease: A Randomized Clinical Trial
Open accessAbstract
Importance: There are no disease-modifying treatments for Alzheimer disease (AD), the most common cause of dementia. Minocycline is anti-inflammatory, protects against the toxic effects of β-amyloid in vitro and in animal models of AD, and is a credible repurposed treatment candidate. Objective: To determine whether 24 months of minocycline treatment can modify cognitive and functional decline in patients with mild AD. Design, Setting, and Participants: Participants were recruited into a double-blind randomized clinical trial from May 23, 2014, to April 14, 2016, with 24 months of treatment and follow-up. This multicenter study in England and Scotland involved 32 National Health Service memory clinics within secondary specialist services for people with dementia. From 886 screened patients, 554 patients with a diagnosis of mild AD (Standardised Mini-Mental State Examination [sMMSE] score ≥24) were randomized. Interventions: Participants were randomly allocated 1:1:1 in a semifactorial design to receive minocycline (400 mg/d or 200 mg/d) or placebo for 24 months. Main Outcomes and Measures: Primary outcome measures were decrease in sMMSE score and Bristol Activities of Daily Living Scale (BADLS), analyzed by intention-to-treat repeated-measures regression. Results: Of 544 eligible participants (241 women and 303 men), the mean (SD) age was 74.3 (8.2) years, and the mean (SD) sMMSE score was 26.4 (1.9). Fewer participants completed 400-mg minocycline hydrochloride treatment (28.8% [53 of 184]) than 200-mg minocycline treatment (61.9% [112 of 181]) or placebo (63.7% [114 of 179]; P < .001), mainly because of gastrointestinal symptoms (42 in the 400-mg group, 15 in the 200-mg group, and 10 in the placebo group; P < .001), dermatologic adverse effects (10 in the 400-mg group, 5 in the 200-mg group, and 1 in the placebo group; P = .02), and dizziness (14 in the 400-mg group, 3 in the 200-mg group, and 1 in the placebo group; P = .01). Assessment rates were lower in the 400-mg group: 68.4% (119 of 174 expected) for sMMSE at 24 months compared with 81.8% (144 of 176) for the 200-mg group and 83.8% (140 of 167) for the placebo group. Decrease in sMMSE scores over 24 months in the combined minocycline group was similar to that in the placebo group (4.1 vs 4.3 points). The combined minocycline group had mean sMMSE scores 0.1 points higher than the placebo group (95% CI, -1.1 to 1.2; P = .90). The decrease in mean sMMSE scores was less in the 400-mg group than in the 200-mg group (3.3 vs 4.7 points; treatment effect = 1.2; 95% CI, -0.1 to 2.5; P = .08). Worsening of BADLS scores over 24 months was similar in all groups: 5.7 in the 400-mg group, 6.6 in the 200-mg group, and 6.2 in the placebo groups (treatment effect for minocycline vs placebo = -0.53; 95% CI, -2.4 to 1.3; P = .57; treatment effect for 400 mg vs 200 mg of minocycline = -0.31; 95% CI, -0.2 to 1.8; P = .77). Results were similar in different patient subgroups and in sensitivity analyses adjusting for missing data. Conclusions and Relevance: Minocycline did not delay the progress of cognitive or functional impairment in people with mild AD during a 2-year period. This study also found that 400 mg of minocycline is poorly tolerated in this population. Trial Registration: isrctn.org Identifier: ISRCTN16105064.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“Minocycline, a tetracycline antibiotic which protects against the toxic effects of β -amyloid in vitro and in animal models of AD, did not delay the progression of cognitive impairment in people with mild AD over a 2-year period in a multicentre clinical trial.(364)”
From Dementia prevention, intervention, and care: 2024 report of the Lancet standing Commission (2024) · cites this paper as [364]
The cited source says what the claim attributes to it.
In the citing paper
“In a transgenic AD mouse model, minocycline prevented Aβ deposition and neuronal death, reduced tau phosphorylation and aggregation, and improved cognitive deficits; however, it failed to delay disease progression in individuals with mild AD in a clinical trial.542”
From Role of neuroinflammation in neurodegeneration development (2023) · cites this paper as [542]
The cited source says what the claim attributes to it.
In the citing paper
“however, it failed to delay disease progression in individuals with mild AD in a clinical trial.542”
From Role of neuroinflammation in neurodegeneration development (2023) · cites this paper as [542]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
McKhann, G. M., Knopman, D. S., Chertkow, H., Hyman, B. T., Jack, C. R., Kawas, C. H., Klunk, W. E., Koroshetz, W. J., Manly, J. J., Mayeux, R., et al. (2011) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2011.03.005 · Cited by 18,657
Cook, R. J., Dickens, B. M., & Fathalla, M. F. (2003) · Oxford University Press eBooks · doi:10.1093/acprof:oso/9780199241323.003.0025 · Cited by 10,825
Neuroinflammation in Alzheimer's disease
Heneka, M. T., Carson, M. J., Khoury, J. E., Landreth, G. E., Brosseron, F., Feinstein, D. L., Jacobs, A. H., Wyss-Coray, T., Vitorica, J., Ransohoff, R. M., et al. (2015) · The Lancet Neurology · doi:10.1016/s1474-4422(15)70016-5 · Cited by 6,226
Alzheimer’s Disease Risk Genes and Mechanisms of Disease Pathogenesis
Karch, C. M., & Goate, A. M. (2015) · Biological Psychiatry · doi:10.1016/j.biopsych.2014.05.006 · Cited by 1,357
Efficacy of minocycline in patients with amyotrophic lateral sclerosis: a phase III randomised trial
Gordon, P. H., Moore, D. H., Miller, R. G., Florence, J. M., Verheijde, J. L., Doorish, C., Hilton, J. F., Spitalny, G. M., MacArthur, R. B., Mitsumoto, H., et al. (2007) · The Lancet Neurology · doi:10.1016/s1474-4422(07)70270-3 · Cited by 649
Bucks, R. S., Ashworth, D. L., Wilcock, G. K., & Siegfried, K. (1996) · Age and Ageing · doi:10.1093/ageing/25.2.113 · Cited by 581
Self-citationInverse association of anti‐inflammatory treatments and Alzheimer's disease
Breitner, J. C. S., Gau, B. A., Welsh-Bohmer, K. A., Plassman, B. L., McDonald, W. M., Helms, M. J., & Anthony, J. C. (1994) · Neurology · doi:10.1212/wnl.44.2.227 · Cited by 569
A Guide to the Standardized Mini-Mental State Examination
Molloy, D. W., & Standish, T. I. M. (1997) · International Psychogeriatrics · doi:10.1017/s1041610297004754 · Cited by 505
NSAIDs and Alzheimer disease: Epidemiological, animal model and clinical studies
McGeer, P. L., & McGeer, E. G. (2007) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2006.03.013 · Cited by 498
Flagged first, then by citations
1 of the 33 references couldn’t be matched to a known paper.
Research works printed but not linked: 1
- Alzheimer’s Disease International, 2015, World Alzheimer Report 2015: The Global Impact of Dementia
Cited by
Sorted by citations
Items 101–194 of 194
Yousefizadeh, A., Piccioni, G., Saidi, A., Triaca, V., Mango, D., & Nisticò, R. (2022) · Pharmacological Research · doi:10.1016/j.phrs.2022.106404 · Cited by 15
New Approaches to Profile the Microbiome for Treatment of Neurodegenerative Disease
Elmaleh, D. R., Downey, M. A., Kundakovic, L., Wilkinson, J. E., Neeman, Z., & Segal, E. (2021) · Journal of Alzheimer s Disease · doi:10.3233/jad-210198 · Cited by 14
Sanchez-Rodriguez, L. M., Khan, A. F., Adewale, Q., Bezgin, G., Therriault, J., Arias, J. F., Servaes, S., Rahmouni, N., Tissot, C., Stevenson, J., et al. (2024) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2024.1383163 · Cited by 16
Fernandes, A. M. A., Caldeira, C., Cunha, C., Ferreiro, E. B., Vaz, A. R., & Brites, D. M. T. O. (2022) · Cells · doi:10.3390/cells11010137 · Cited by 14
Luo, S., Li, L.-Y., Guo, L.-Z., Wang, L., Wang, Y., Chen, N., & Wang, E. (2022) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2022.978768 · Cited by 15
Topalis, V., Voros, C., & Ziaka, M. (2025) · Journal of Geriatric Psychiatry and Neurology · doi:10.1177/08919887251361578 · Cited by 14
Lasch, F., Guizzaro, L., Pétavy, F., & Gallo, C. (2022) · Statistics in Biopharmaceutical Research · doi:10.1080/19466315.2022.2055633 · Cited by 12
Cuní‐López, C., Stewart, R., White, A. R., & Quek, H. (2023) · Journal of Neuroimmunology · doi:10.1016/j.jneuroim.2023.578017 · Cited by 9
Chen, Y., Pan, Y., Xie, Y., Shi, Y., Lu, Y., Xia, Y., Su, W., Chen, X., Li, Z., Wang, M., et al. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-02037-2 · Cited by 12
Chang, C.-H., Liu, C., Chen, S.-J., & Tsai, H. (2021) · Scientific Reports · doi:10.1038/s41598-021-02040-5 · Cited by 11
Recent Updates on the Development of Therapeutics for the Targeted Treatment of Alzheimer’s Disease
Rajput, S., Malviya, R., Bahadur, S., & Puri, D. (2023) · Current Pharmaceutical Design · doi:10.2174/0113816128274618231105173031 · Cited by 12
Potter, H., Boyd, T. D., Clarke, P., Pelak, V. S., & Tyler, K. L. (2020) · F1000Research · doi:10.12688/f1000research.23729.1 · Cited by 11
Tackling Alzheimer’s Disease with Existing Drugs: A Promising Strategy for Bypassing Obstacles
Rampa, A., Gobbi, S., Belluti, F., & Bisi, A. (2020) · Current Medicinal Chemistry · doi:10.2174/0929867327666200831140745 · Cited by 11
Shifting Microglial Phenotypes: Targeting Disease-Associated Microglia in Neurodegeneration
Sasidharan, A., Somayaji, Y., & Fernandes, R. (2025) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.5c00159 · Cited by 11
Doxycycline: An essential tool for Alzheimer’s disease
Forloni, G. (2025) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2025.118159 · Cited by 11
Zhan, F., Dong, Y., Zhou, L., Li, X., Zhou, Z., & Xu, G. (2024) · Aging · doi:10.18632/aging.205528 · Cited by 11
Targeting tau in Alzheimer’s Disease: rationale, approach and challenges
Aslanyan, A., Foiani, M. S., Giovannucci, T. A., McDade, E., Duff, K., Mummery, C. J., Schöll, M., Wildsmith, K. R., & Paterson, R. W. (2026) · Molecular Neurodegeneration · doi:10.1186/s13024-026-00925-5 · Cited by 10
de Oliveira, B. S. A., Milanezi, D. S., Gonzaga, P. D. V., Detoni, F. R., & Soriano, R. N. (2022) · Heliyon · doi:10.1016/j.heliyon.2022.e12172 · Cited by 10
Asaba, T., Hamano, S., Nanmo, A., Seo, J., Kageyama, T., & Fukuda, J. (2025) · Regenerative Therapy · doi:10.1016/j.reth.2025.06.013 · Cited by 8
Severe infections as a gateway to dementia
Mika Kivimaki, B., & Walker, K. A. (2024) · Nature Aging · doi:10.1038/s43587-024-00643-x · Cited by 8
Lei, H., Chen, X., Ruan, L., Liu, X., Ye, F., Li, K., Cheng, W., Yu, B., Di, C., & Di, C. (2025) · Ageing Research Reviews · doi:10.1016/j.arr.2025.102927 · Cited by 7
Contributions of animal models of cognitive disorders to neuropsychopharmacology
Deguil, J., & Bordet, R. (2021) · Therapies · doi:10.1016/j.therap.2021.02.001 · Cited by 6
Gao, L., Shuai, Y., Wen, L., Zhang, H., Zhang, Y., & Zhang, X. (2022) · Medicine · doi:10.1097/md.0000000000031637 · Cited by 6
Li, J., Zhang, F., Zhao, L., & Dong, C. (2023) · Reviews in the Neurosciences · doi:10.1515/revneuro-2023-0006 · Cited by 6
Wang, Z. P., Li, X., Matsumoto, N., Venkatesan, M., Chang, J.-H., Moran, J., Choi, H., Li, B., Meng, Y., Hernandez, M. E., et al. (2025) · BioData Mining · doi:10.1186/s13040-025-00466-5 · Cited by 7
Molecular and Therapeutic Targets for Amyloid-beta Plaques in Alzheimer's Disease: A Review Study
Thomas, J., & WILSON, S. K. (2021) · Basic and Clinical Neuroscience Journal · doi:10.32598/bcn.2021.3522.1 · Cited by 6
Bath, P. M., Phan, E. P., Clay, G., Dawson, J., Malhotra, P., Howard, R. J., Pal, S., Wardlaw, J. M., Quinn, T., & Macleod, M. R. (2024) · F1000Research · doi:10.12688/f1000research.157890.1 · Cited by 4
Self-citationCuní‐López, C., Stewart, R., Okano, S., Redlich, G. L., Appleby, M. W., White, A. R., & Quek, H. (2025) · Scientific Reports · doi:10.1038/s41598-025-92593-6 · Cited by 5
Recent advances in small molecule stimulation of regeneration and repair
Silpa, L., Sim, R. R. Y., & Russell, A. J. (2022) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2022.128601 · Cited by 5
Patient-specific monocyte-derived microglia as a screening tool for neurodegenerative diseases
Quek, H., & White, A. (2022) · Neural Regeneration Research · doi:10.4103/1673-5374.355740 · Cited by 5
Zhang, J., Huang, Y., Chen, Y., Zhang, Y., Chen, J., Huang, Y., Zhong, H., He, H., Dai, X., Yan, X., et al. (2026) · Immunity · doi:10.1016/j.immuni.2026.03.007 · Cited by 6
Identifying synergistic combinations of repurposed treatments for Alzheimer’s Disease
Ballard, C. G., Sultana, J., Doherty, P., Williams, G. H., & Corbett, A. (2025) · The Journal of Prevention of Alzheimer s Disease · doi:10.1016/j.tjpad.2025.100329 · Cited by 5
Self-citationDiagnostic utility of biomarkers in progressive supranuclear palsy: toward a biotyping framework
Ryan, C. B., Camargo, C. J., Salan, T., Pallikkuth, S., Gao, H., & Govind, V. (2025) · Journal of Neurology · doi:10.1007/s00415-025-13539-6 · Cited by 6
Melink, Z., Lustberg, M. B., Schnell, P., Mezzanotte-Sharpe, J., & Orchard, T. (2024) · Breast Cancer Research and Treatment · doi:10.1007/s10549-024-07457-w · Cited by 4
Microglial depletion rescues spatial memory impairment caused by LPS administration in adult mice
Zong, T., Li, N., Han, F., Liu, J., Deng, M., Li, V. W. T., Zhang, M., Zhou, Y., & Yu, M. (2024) · PeerJ · doi:10.7717/peerj.18552 · Cited by 5
Cui, T., Yu, P., Feng, X., Song, Q., Yang, D., Li, M., & Feng, L. (2024) · Metabolic Brain Disease · doi:10.1007/s11011-024-01444-2 · Cited by 4
Liu, M., Beckett, T. L., Thomason, L. A. M., Dorr, A. E., Stefanovic, B., & McLaurin, J. (2021) · Brain Research · doi:10.1016/j.brainres.2020.147233 · Cited by 5
Pragmatic Trials and Repurposed Drugs for Alzheimer Disease
Schneider, L. S. S. (2019) · JAMA Neurology · doi:10.1001/jamaneurol.2019.3784 · Cited by 5
Bhandari, A. K., Dhami, A. S., Hemanthlumar, R. T., Mishra, N., Joslyn, B., Roy, S., Srinivasan, J., Prajapati, K. P., Kar, K., & Anand, B. G. (2025) · Ageing Research Reviews · doi:10.1016/j.arr.2025.102879 · Cited by 4
The role of microbiota modulation in preventing Alzheimer’s disease- a review
Strzępa, A., & Szczepanik, M. (2025) · Pharmacological Reports · doi:10.1007/s43440-025-00796-5 · Cited by 3
Sardari, M., Sahafi, O. H., & Rezayof, A. (2025) · Brain Research · doi:10.1016/j.brainres.2025.150040 · Cited by 3
Siddiqui, A. M., Sabljic, T. F., & Ball, A. K. (2022) · International Journal of Neuroscience · doi:10.1080/00207454.2022.2142579 · Cited by 3
Roberts, J. A., Varma, V. R., Jones, A., & Thambisetty, M. (2024) · Journal of Alzheimer s Disease · doi:10.3233/jad-240680 · Cited by 5
Luque‐Campos, N., Riquelme, R., Molina, L., Canedo-Marroquín, G., Vega-Letter, A. M., Luz‐Crawford, P., & Bustamante-Barrientos, F. A. (2023) · Frontiers in Physiology · doi:10.3389/fphys.2023.1217815 · Cited by 4
Turning microglia neuroprotective: Towards connexin43-specific therapy of Alzheimer’s diseasePreprint
Su, Y., Li, H., Zhang, W., Tao, S., Wang, Q., Zhou, M., Tang, Y., Chen, H., Verkhratsky, A., Zha, Z., et al. (2024) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2024.08.06.606883 · Cited by 3
Atypical Tetracyclines Promote Longevity and Ferroptotic Neuroprotection via Translation Attenuation
Clay, K. J., Sánchez-Alavez, M., Newman, I., Na, N., Espinoza, A. P. V., To, A., Saad, S., Cline, H. T., & Petrascheck, M. (2026) · Aging Cell · doi:10.1111/acel.70587 · Cited by 3
Network Pharmacology for Drug Repositioning in Anti-Alzheimer’s Drug Development
Dash, R., Munni, Y. A., Mitra, S., Dash, N., & Moon, I. S. (2023) · Neuromethods · doi:10.1007/978-1-0716-3311-3_15 · Cited by 4
Therapeutic Modalities Targeting Tau Protein in Alzheimer’s Disease
Schreiner, T. G., Iacob, L., Vasilache, C., & Schreiner, O. D. (2025) · Journal of dementia and Alzheimer's disease · doi:10.3390/jdad2030032 · Cited by 2
Vorobev, S. V., Emelin, А. Y., Kuznetsova, R. N., & Kudryavtsev, I. V. (2021) · Neurology Bulletin · doi:10.17816/nb34654 · Cited by 2
Chen, Q., Yan, W., & Geng, N. (2022) · Evidence-based Complementary and Alternative Medicine · doi:10.1155/2022/7604741 · Cited by 2
RetractedObesity, inflammation, and aging
Chu, J. J., & Mehrzad, R. (2022) · Elsevier eBooks · doi:10.1016/b978-0-323-90960-0.00001-1 · Cited by 1
Kratimenos, P., Simonti, G., & Kinney, H. C. (2025) · Pediatric Research · doi:10.1038/s41390-025-04031-y · Cited by 1
Treatment options for Alzheimer’s Disease: An overview of the amyloid, tau, and alternate hypotheses
Eroltu, K. (2023) · Journal of High School Science · doi:10.64336/001c.89250 · Cited by 1
She, L., Li, M., Chen, F., Wu, X., Zhang, J., Jiang, W., Sun, Z., Li, L., Ren, J., Chen, D., et al. (2026) · Pharmacological Research · doi:10.1016/j.phrs.2026.108280 · Cited by 1
Human Microglial Molecular Alterations in Aging and Alzheimer’s Disease
Baldo, K. A. T., Gozlan, E., Chidebe, E. O., Awogbindin, I. O., Prieto, M. O., Dalmacio, L. M. M., Ben-Azu, B., Frenkel, D., & Tremblay, M. (2026) · Cells · doi:10.3390/cells15131159 · Cited by 1
Depression in neurodegenerative disease: neurobiological mechanisms and emerging treatments
Costello, H., Reeves, S., Glue, P., Young, A. H., & Howard, R. J. (2026) · Molecular Psychiatry · doi:10.1038/s41380-026-03728-8 · Cited by 1
Self-citationMolecular and environmental contributors to neurological complications in sickle cell disease
Karkoska, K. A., Gollamudi, J., & Hyacinth, H. I. (2023) · Experimental Biology and Medicine · doi:10.1177/15353702231187646 · Cited by 1
Cytokines in Neurodegenerative Disorders
Pahan, K. (2024) · Springer eBooks · doi:10.1007/978-3-031-68237-7_12 · Cited by 1
On the semantics of clinical trials. The case of a ‘pragmatic’ trial in Alzheimer’s disease
Dal‐Ré, R. (2019) · European Journal of Neurology · doi:10.1111/ene.14141 · Cited by 1
Minocycline—A Lesson From a Failure—Reply
Howard, R. J., & Gray, R. G. (2020) · JAMA Neurology · doi:10.1001/jamaneurol.2020.1157 · Cited by 1
Self-citationMinocycline—A Lesson From a Failure
Granzotto, A., & Sensi, S. L. (2020) · JAMA Neurology · doi:10.1001/jamaneurol.2020.1154 · Cited by 1
Sanchez-Rodriguez, L. M., Khan, A. F., Adewale, Q., Bezgin, G., Therriault, J., Arias, J. F., Servaes, S., Rahmouni, N., Tissot, C., Stevenson, J., et al. (2023) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2023.09.15.557737 · Cited by 2
Atypical tetracyclines promote longevity and ferroptotic neuroprotection via translation attenuationPreprint
Clay, K. J., Sánchez-Alavez, M., Newman, I. A., Na, N., Espinoza, A. P. V., To, A., Saad, S., Cline, H. T., & Petrascheck, M. (2026) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.64898/2026.01.09.698733 · Cited by 1
Chemobrain: Mysteries and the importance of their revelation
Tuncer, M. (2022) · Hacettepe University Journal of the Faculty of Pharmacy · doi:10.52794/hujpharm.1100269
Cuní‐López, C., Stewart, R., Okano, S., Redlich, G. L., Appleby, M. W., White, A. R., & Quek, H. (2023) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2023.08.17.552618
Neuroinflammation Imaging in Neurodegenerative Diseases
Hammoud, D. A., & Herscovitch, P. (2023) · Springer eBooks · doi:10.1007/978-3-031-35098-6_9
Society Interacting with Brain, Cognition, and Health in Late Life
Chey, J. (2023) · Cambridge University Press eBooks · doi:10.1017/9781108974325.008
Psychoneuroimmunology Linking Social Isolation with Cognitive Aging
Lee, S. (2023) · Cambridge University Press eBooks · doi:10.1017/9781108974325.011
Transforming Alzheimer's Treatment: Unveiling New Potential with Drug Repurposing Strategies
Mishra, A. S., Vasanthan, M. V. M., Ghosh, B., & Sivakumar, P. M. (2025) · Current Medicinal Chemistry · doi:10.2174/0109298673341391241231054936
Role of Omega-3s in Functional Foods
Nath, P. C., Ojha, A., Sharma, M., Inbaraj, B. S., Sridhar, K., Naik, P. K., Dikkala, P. K., & Burla, V. S. S. (2025) · Royal Society of Chemistry eBooks · doi:10.1039/9781837673292-00062
Lasch, F., Guizzaro, L., & Loh, W. W. (2025) · Statistics in Biopharmaceutical Research · doi:10.1080/19466315.2025.2573322
Nordengen, K., Kirsebom, B.-E., Richter, G., Pålhaugen, L., Gísladóttir, B., Siafarikas, N., Nakling, A. E., Rongve, A., Bråthen, G., Grøntvedt, G. R., et al. (2024) · Figshare · doi:10.6084/m9.figshare.26653528
Nordengen, K., Kirsebom, B.-E., Richter, G., Pålhaugen, L., Gísladóttir, B., Siafarikas, N., Nakling, A. E., Rongve, A., Bråthen, G., Grøntvedt, G. R., et al. (2024) · Figshare · doi:10.6084/m9.figshare.26653531
Voigt, S., Koemans, E. A., Rasing, I., van Etten, E. S., Terwindt, G. M., Baas, F., Kaushik, K., van Es, A. C. G. M., van Buchem, M. A., van Osch, M. J. P., et al. (2023) · Figshare · doi:10.6084/m9.figshare.23298855
Nordengen, K., Kirsebom, B.-E., Richter, G., Pålhaugen, L., Gísladóttir, B., Siafarikas, N., Nakling, A. E., Rongve, A., Bråthen, G., Grøntvedt, G. R., et al. (2024) · Figshare · doi:10.6084/m9.figshare.26653534
Sex Differences in Neuroinflammation and Cognitive Resilience in Aging
Han, J. W. (2026) · Sex- and Gender-Specific Biomedicine · doi:10.65400/sgbm.2026.1.1.25
Ju, M., Shen, H., Zhang, X., Tian, M., & Zhang, L. (2026) · Biochemistry and Biophysics Reports · doi:10.1016/j.bbrep.2026.102475
Lee, A. L. Y., Wei, A. C., & Yeong, K. Y. (2026) · Drug Discovery Today · doi:10.1016/j.drudis.2026.104651
Zhang, Y., Zhao, J., Fan, Z., Wang, X., Shi, X., Wang, X., Wan, T., Du, F., Wu, K., & Jiang, W. (2026) · Journal of Neuroimmune Pharmacology · doi:10.1007/s11481-026-10290-1
In vitro and in vivo study of the effects of Levetiracetam on activated microglia during sepsis
Fleurance, R. (2021) · theses.fr (ABES) · doi:10.70675/0a82ed6ez6595z4366z832fz70cbe839c7ff
Sun, X., An, Z., Wang, S., & Wang, K. (2026) · npj Parkinson s Disease · doi:10.1038/s41531-026-01374-z
Minocycline differentially modulates human spatial memory systemsPreprint
Bird, C. M., Harrison, N. A., & Berens, S. C. (2020) · OSF Preprints (OSF Preprints)
Small Molecules as Anti-Alzheimer’s Scaffolds
Hazra, R., Roy, S., Gayen, S., Parui, A., Arshad, A., Roy, N., & Sarkar, A. N. (2026) · BENTHAM SCIENCE PUBLISHERS eBooks · doi:10.2174/9798898815646126010013
Reshaping the immune landscape: next-generation microglia-targeted therapies for Alzheimer’s disease
Wu, J., Zhao, J. J., Chen, S. Y., & Xu, F. (2026) · Biological Research · doi:10.1186/s40659-026-00716-8
Precision therapeutics and innovative clinical trial design in neurodegenerative diseases
Garcia, A., Delgado-Uriarte, J. C., & Cervantes‐Arriaga, A. (2026) · Revista de investigaci�n Cl�nica · doi:10.1016/j.ric.2026.100050
Chemotherapy-Induced Brain Damage: Mechanisms and Insights from Rodent Models
Veljković, M., Džopalić, T., Randjelović, P. J., Dragonjić, L. P., Milenković, J., & Ilić, I. (2026) · Brain Sciences · doi:10.3390/brainsci16070750 · Cited by 1
Boşgelmez, İ. İ., Mertaş, B., & Deliser, H. (2026) · Frontiers in Toxicology · doi:10.3389/ftox.2026.1871830
Novel insights of minocycline as a neurovascular protective agent in retinitis pigmentosa
Chen, Y., Shi, Y., Chen, G., Xie, Y., Xiao, Z., Wu, H., Chen, X., Xia, Y., Wang, M., Liang, D., et al. (2026) · British Journal of Ophthalmology · doi:10.1136/bjo-2025-328440
Imbimbo, B. P., Pomara, N., Pini, L., & Frederiksen, K. S. (2026) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2026.119943
Hashioka, S. (2026) · International Journal of Molecular Sciences · doi:10.3390/ijms27198533
Wang, T., Wang, L., Cao, J., Zhao, Y., He, Z., & Lu, F. (2026) · Frontiers in Immunology · doi:10.3389/fimmu.2026.1956600
Gogu, M.-R., Costăchescu, I., Stanciu, G. D., Tamba, B.-I., Ciorpac, M., & Gorgan, L. (2026) · Pharmaceuticals · doi:10.3390/ph19101603
Sharma, R., Kumar, G., & Thakur, A. (2026) · Inflammopharmacology · doi:10.1007/s10787-026-02433-w
Metadata
- Authors
- Howard, R., Zubko, O., Bradley, R., Harper, E., Pank, L., O’Brien, J., Fox, C., Tabet, N., Livingston, G., Bentham, P., McShane, R., Burns, A., Ritchie, C., Reeves, S., Lovestone, S., Ballard, C., Noble, W., Nilforooshan, R., Wilcock, G., Gray, R., & for the Minocycline in Alzheimer Disease Efficacy (MADE) Trialist Group
- Affiliations
- University College London (GB)
- King's College London (GB)
- University of Oxford (GB)
- Department of Psychiatry, University of Cambridge, Cambridge, United Kingdom
- University of East Anglia (GB)
- University of Sussex (GB)
- National Health Service (GB)
- University of Manchester (GB)
- University of Edinburgh (GB)
- University of Exeter (GB)
- Corresponding author
- Howard, Robert
- ORCID
- Venue
- JAMA Neurology
- Publisher
- American Medical Association (AMA)
- Published
- 2020-02-01
- Volume
- 77
- Issue
- 2
- Pages
- 164
- ISSN
- 2168-6149 (ISSN-L)
- PMC
- PMC6865324
- OpenAlex
- W2984563923
- Cited by
- 194
- References
- 33
- Citations by year
- 2026: 24 · 2025: 22 · 2024: 30 · 2023: 26 · 2022: 38 · 2021: 26 · 2020: 26
- FWCI
- 15.78
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- cc-by
- Locations
- JAMA Neurology (publishedVersion, cc-by)
- Research Portal (King's College London) (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- UEA Digital Repository (University of East Anglia) (acceptedVersion)
- Sussex Research Online (University of Sussex) (submittedVersion, cc-by)
- UCL Discovery (University College London) (submittedVersion)
- Figshare (submittedVersion, cc-by)
- Open Research Exeter (University of Exeter) (submittedVersion, cc-by)
- Edinburgh Research Explorer (University of Edinburgh) (submittedVersion, cc-by)
- Royal Devon and Exeter Research Repository (Royal Devon and Exeter) (submittedVersion)
- Funders
- South London and Maudsley NHS Foundation Trust
- Sussex Partnership NHS Foundation Trust
- National Institute for Health and Care Research (NF-SI-0616-10042, NIHR/CS/010/019)
- St George's University Hospitals NHS Foundation Trust
- Oxford Health NHS Foundation Trust
- Medical Research Council
- Topics
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Health Sciences › Medicine › Pharmacology (medical) › Cholinesterase and Neurodegenerative Diseases
- Keywords
- minocycline, Alzheimer's disease, mild Alzheimer disease, disease-modifying therapy, drug repurposing, anti-inflammatory therapy, amyloid-beta, cognitive decline, functional decline, activities of daily living, dose comparison, gastrointestinal adverse effects, dermatologic adverse effects, dizziness, medication adherence, memory clinics, dementia services, Mini-Mental State Examination
- MeSH terms
- Activities of Daily Living, Aged, Aged, 80 and over, Alzheimer Disease, Dose-Response Relationship, Drug, Double-Blind Method, Female, Humans, Male, Minocycline, Treatment Outcome, Disease Progression, Neuroprotective Agents
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
